Insider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 4,299 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the sale, the director owned 8,118 shares of the company's stock, valued at approximately $1,358,628.48. The trade was a 34.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Gail Boxer Marcus also recently made the following trade(s):

• On Tuesday, June 10th, Gail Boxer Marcus sold 4,000 shares of Natera stock. The shares were sold at an average price of $164.44, for a total transaction of $657,760.00.
• On Thursday, May 1st, Gail Boxer Marcus sold 4,000 shares of Natera stock. The stock was sold at an average price of $151.61, for a total transaction of $606,440.00.

Natera Trading Down 0.0%

Shares of NASDAQ:NTRA traded down $0.07 during trading on Thursday, reaching $161.50. 468,868 shares of the stock were exchanged, compared to its average volume of 1,422,668. The firm has a market cap of $22.05 billion, a PE ratio of -109.86 and a beta of 1.73. The stock has a 50-day moving average price of $160.18 and a 200-day moving average price of $158.47. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The firm's quarterly revenue was up 36.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.56) earnings per share. On average, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently made changes to their positions in the business. LRI Investments LLC acquired a new position in shares of Natera during the fourth quarter valued at about $29,000. Bank of Jackson Hole Trust bought a new position in shares of Natera during the 1st quarter valued at approximately $29,000. Rakuten Securities Inc. increased its position in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after buying an additional 119 shares during the last quarter. TCTC Holdings LLC raised its position in shares of Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after purchasing an additional 124 shares during the period. Finally, ORG Partners LLC bought a new position in shares of Natera in the first quarter worth $32,000. Institutional investors own 99.90% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on NTRA shares. Morgan Stanley boosted their price target on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Piper Sandler lifted their target price on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. UBS Group increased their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, Barclays boosted their target price on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $184.63.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.